Institution
National Marrow Donor Program
Nonprofit•Minneapolis, Minnesota, United States•
About: National Marrow Donor Program is a nonprofit organization based out in Minneapolis, Minnesota, United States. It is known for research contribution in the topics: Transplantation & Hematopoietic stem cell transplantation. The organization has 280 authors who have published 610 publications receiving 23077 citations.
Topics: Transplantation, Hematopoietic stem cell transplantation, Population, Human leukocyte antigen, Haplotype
Papers published on a yearly basis
Papers
More filters
Anthony Nolan1, University of Oxford2, Biomedical Primate Research Centre3, Kettering University4, Hoffmann-La Roche5, University of Texas MD Anderson Cancer Center6, Fred Hutchinson Cancer Research Center7, University of Washington8, University of California, Los Angeles9, Hallym University10, University of Geneva11, National Marrow Donor Program12, Medical University of Vienna13, Stanford University14, Harvard University15, University of Cambridge16
TL;DR: This report documents the additions and revisions to the nomenclature of HLA specificities following the principles established in previous reports.
Abstract: The WHO Nomenclature Committee for Factors of the HLA System met following the 14th International HLA and Immunogenetics Workshop in Melbourne, Australia in December 2005 and Buzios, Brazil during the 15th International HLA and Immunogenetics Workshop in September 2008. This report documents the additions and revisions to the nomenclature of HLA specificities following the principles established in previous reports (1–18).
2,390 citations
Fred Hutchinson Cancer Research Center1, Center for International Blood and Marrow Transplant Research2, University of California, San Francisco3, National Marrow Donor Program4, University of Texas MD Anderson Cancer Center5, Thomas Jefferson University Hospital6, Georgetown University Medical Center7, University of Minnesota8, University of New Mexico9
TL;DR: In multivariate modeling, patient age, race, disease stage, and cytomegalovirus status were as predictive of survival as donor HLA matching, and high-resolution DNA matching for HLA-A, -B, -C, and -DRB1 alleles is associated with higher rates of survival.
1,105 citations
University of South Florida1, Medical College of Wisconsin2, Fred Hutchinson Cancer Research Center3, Emory University4, University of Florida5, Harvard University6, Washington University in St. Louis7, Dalhousie University8, Dresden University of Technology9, Stanford University10, Oregon Health & Science University11, University of Utah12, University of Pennsylvania13, University of Michigan14, Virginia Commonwealth University15, Mayo Clinic16, University of Texas MD Anderson Cancer Center17, National Institutes of Health18, Rutgers University19, Ottawa Hospital Research Institute20, National Marrow Donor Program21
TL;DR: A phase 3, multicenter, randomized trial of transplantation of peripheral-blood stem cells versus bone marrow from unrelated donors did not detect significant survival differences, and exploratory analyses of secondary end points indicated that peripheral- Blood stem cells may reduce the risk of graft failure, whereas bone marrow may reduceThe risk of chronic GVHD.
Abstract: BACKGROUND Randomized trials have shown that the transplantation of filgrastim-mobilized peripheral-blood stem cells from HLA-identical siblings accelerates engraftment but increases the risks of acute and chronic graft-versus-host disease (GVHD), as compared with the transplantation of bone marrow. Some studies have also shown that peripheral-blood stem cells are associated with a decreased rate of relapse and improved survival among recipients with high-risk leukemia. METHODS We conducted a phase 3, multicenter, randomized trial of transplantation of peripheral-blood stem cells versus bone marrow from unrelated donors to compare 2-year survival probabilities with the use of an intention-to-treat analysis. Between March 2004 and September 2009, we enrolled 551 patients at 48 centers. Patients were randomly assigned in a 1:1 ratio to peripheral-blood stem-cell or bone marrow transplantation, stratified according to transplantation center and disease risk. The median follow-up of surviving patients was 36 months (interquartile range, 30 to 37). RESULTS The overall survival rate at 2 years in the peripheral-blood group was 51% (95% confidence interval [CI], 45 to 57), as compared with 46% (95% CI, 40 to 52) in the bone marrow group (P = 0.29), with an absolute difference of 5 percentage points (95% CI, −3 to 14). The overall incidence of graft failure in the peripheral-blood group was 3% (95% CI, 1 to 5), versus 9% (95% CI, 6 to 13) in the bone marrow group (P = 0.002). The incidence of chronic GVHD at 2 years in the peripheral-blood group was 53% (95% CI, 45 to 61), as compared with 41% (95% CI, 34 to 48) in the bone marrow group (P = 0.01). There were no significant between-group differences in the incidence of acute GVHD or relapse. CONCLUSIONS We did not detect significant survival differences between peripheral-blood stem-cell and bone marrow transplantation from unrelated donors. Exploratory analyses of secondary end points indicated that peripheral-blood stem cells may reduce the risk of graft failure, whereas bone marrow may reduce the risk of chronic GVHD. (Funded by the National Heart, Lung, and Blood Institute–National Cancer Institute and others; ClinicalTrials.gov number, NCT00075816.)
715 citations
TL;DR: Age should be considered when selecting among comparably HLA-matched volunteer donors and the use of younger donors may lower the incidence of GVHD and improve survival after bone marrow transplantation.
620 citations
TL;DR: Genetic profiling revealed that molecular subgroups of patients undergoing allogeneic hematopoietic stem‐cell transplantation for MDS may inform prognostic stratification and the selection of conditioning regimen.
Abstract: BackgroundGenetic mutations drive the pathogenesis of the myelodysplastic syndrome (MDS) and are closely associated with clinical phenotype. Therefore, genetic mutations may predict clinical outcomes after allogeneic hematopoietic stem-cell transplantation. MethodsWe performed targeted mutational analysis on samples obtained before transplantation from 1514 patients with MDS who were enrolled in the Center for International Blood and Marrow Transplant Research Repository between 2005 and 2014. We evaluated the association of mutations with transplantation outcomes, including overall survival, relapse, and death without relapse. ResultsTP53 mutations were present in 19% of the patients and were associated with shorter survival and a shorter time to relapse than was the absence of TP53 mutations, after adjustment for significant clinical variables (P<0.001 for both comparisons). Among patients 40 years of age or older who did not have TP53 mutations, the presence of RAS pathway mutations was associated with...
508 citations
Authors
Showing all 282 results
| Name | H-index | Papers | Citations |
|---|---|---|---|
| Daniel J. Weisdorf | 122 | 917 | 68271 |
| Jerome Ritz | 120 | 644 | 47987 |
| Joseph H. Antin | 115 | 669 | 44609 |
| Stephen E. Sallan | 98 | 337 | 30015 |
| Jeffrey S. Miller | 84 | 500 | 28363 |
| Elizabeth Murphy | 66 | 259 | 16966 |
| Nancy A. Kernan | 61 | 264 | 15913 |
| Steven M. Devine | 60 | 266 | 16516 |
| Navneet S. Majhail | 54 | 375 | 10050 |
| Linda J. Burns | 51 | 195 | 9659 |
| Paul L. Auer | 49 | 157 | 10559 |
| Dennis L. Confer | 46 | 174 | 10089 |
| Malek Kamoun | 42 | 177 | 6251 |
| Stephen R. Spellman | 40 | 200 | 5934 |
| Mark R. Litzow | 39 | 87 | 7218 |